Patents by Inventor Giovanni Coppola

Giovanni Coppola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors
    Publication number: 20240148774
    Abstract: The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 9, 2024
    Inventors: Gaurang Patel, Ying Hu, Kavita Praveen, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Carmelo Romano
  • Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors
    Publication number: 20240102013
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (SOS2) variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: October 12, 2023
    Publication date: March 28, 2024
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Goncalo Abecasis, Aris Baras
  • Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors
    Patent number: 11865134
    Abstract: The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: January 9, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gaurang Patel, Ying Hu, Kavita Praveen, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Carmelo Romano
  • Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
    Patent number: 11845989
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: December 19, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola, Gaurang Patel, Ying Hu, Carmelo Romano, Giusy Della Gatta, Trikaldarshi Persaud
  • Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors
    Patent number: 11820982
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human Son of Sevenless 2 (SOS2) variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Goncalo Abecasis, Aris Baras
  • Kelch Domain Containing 7B (KLHDC7B) Variants And Uses Thereof
    Publication number: 20230366024
    Abstract: The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: April 19, 2023
    Publication date: November 16, 2023
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
  • Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
    Patent number: 11767526
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: September 26, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola, Carmelo Romano
  • Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) Variants And Uses Thereof
    Publication number: 20230287422
    Abstract: The present disclosure provides methods of treating subjects having Alzheimer's Disease, and methods of identifying subjects having an increased risk of developing Alzheimer's Disease.
    Type: Application
    Filed: January 10, 2023
    Publication date: September 14, 2023
    Inventors: Jan Freudenberg, Giovanni Coppola, Katherine Siminovitch
  • Methods Of Treating Headaches And Migraines With Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) Inhibitors
    Publication number: 20230279400
    Abstract: The present disclosure provides methods of treating a subject having a headache or a migraine or preventing a subject from developing a headache or a migraine by administering an Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) inhibitor, and methods of identifying subjects having an increased risk of developing a headache or a migraine.
    Type: Application
    Filed: November 21, 2022
    Publication date: September 7, 2023
    Inventors: Kavita Praveen, Giovanni Coppola, Aris Baras
  • Treatment Of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors
    Publication number: 20230250434
    Abstract: The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.
    Type: Application
    Filed: October 13, 2022
    Publication date: August 10, 2023
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Carmelo Romano, Santiago Mendez Huergo, Jonathan Weyne, Tave Van Zyl
  • Kelch domain containing 7B (KLHDC7B) variants and uses thereof
    Patent number: 11674177
    Abstract: The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: June 13, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
  • Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors
    Publication number: 20230108957
    Abstract: The present disclosure provides methods of treating subjects having psychiatric disorders and/or psychiatric disorder-associated MRI phenotypes, and methods of identifying subjects having an increased risk of developing psychiatric disorders and/or psychiatric disorder-associated MRI phenotypes.
    Type: Application
    Filed: September 29, 2022
    Publication date: April 6, 2023
    Inventors: Manuel Allen Revez Ferreira, Veera Rajagopal, Giovanni Coppola, Jonathan Marchini, Aris Baras
  • Treatment Of Glaucoma With Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) Inhibitors
    Publication number: 20230099109
    Abstract: The present disclosure provides methods of treating subjects having glaucoma or elevated intraocular pressure (IOP), methods of identifying subjects having an increased risk of developing glaucoma or developing elevated IOP, methods of detecting human Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) variant nucleic acid molecules and variant polypeptides, and ARHGEF12 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: September 28, 2022
    Publication date: March 30, 2023
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Claudia Schurmann
  • Modulation Of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2)-Mediated Immune Response
    Publication number: 20230059929
    Abstract: The present disclosure provides methods of treating subjects having an immune disorder by administering a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor to the subject, and optionally an Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) agonist or inhibitor and/or an HLA-Aw19 inhibitor, and also provides methods of identifying subjects having an increased risk for developing an MHC-I-opathy.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 23, 2023
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Jack A. Kosmicki, Manuel Allen Revez Ferreira, Carmelo Romano
  • Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) Inhibitors
    Publication number: 20230034093
    Abstract: The present disclosure provides methods of treating subjects having cognitive impairment or at risk of developing cognitive impairment, and methods of identifying subjects having an increased risk of developing cognitive impairment.
    Type: Application
    Filed: June 30, 2022
    Publication date: February 2, 2023
    Inventors: Jonathan Marchini, Manuel Allen Revez Ferreira, Giovanni Coppola, Goncalo Abecasis, Aris Baras
  • Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
    Patent number: 11512309
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: November 29, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola
  • Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors
    Publication number: 20220370489
    Abstract: The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.
    Type: Application
    Filed: February 23, 2022
    Publication date: November 24, 2022
    Inventors: Gaurang Patel, Ying Hu, Kavita Praveen, Giovanni Coppola, Goncalo Abecasis, Aris Baras, Carmelo Romano
  • Materials And Methods Of Treating MHC-1-Opathy Risk Haplotypes
    Publication number: 20220323581
    Abstract: The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor in combination with an HLA-A29 or HLA-B27 inhibitory nucleic acid molecule.
    Type: Application
    Filed: April 6, 2022
    Publication date: October 13, 2022
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Jack A. Kosmicki, Manuel Allen Revez Ferreira, Carmelo Romano
  • Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors
    Publication number: 20220089664
    Abstract: The present disclosure provides methods of treating subjects having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, and methods of detecting Angiopoietin-Like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: July 27, 2021
    Publication date: March 24, 2022
    Inventors: Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola, Gaurang Patel, Ying Hu, Carmelo Romano, Giusy Della Gatta, Trikaldarshi Persaud
  • Synaptojanin 2 (SYNJ2) Variants And Uses Thereof
    Publication number: 20220064735
    Abstract: The present disclosure provides methods of treating patients having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, methods of detecting human Synaptojanin-2 (SYNJ2) variant nucleic acid molecules and variant polypeptides, and SYNJ2 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 3, 2022
    Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis